Here are a few genes that have historically shown records of enhancing drug activity upon CRISPR knockout:

1. **GPR35**: GPR35 is a G-protein coupled receptor that has been implicated in various physiological and pathological processes, including immune response modulation and cellular proliferation. Knockout studies using CRISPR technology have demonstrated that GPR35 plays a significant role in enhancing the sensitivity of certain cancer cells to chemotherapeutic agents. By disrupting GPR35, researchers observed a reduction in drug resistance, which was attributed to its role in cellular signaling pathways that promote survival and growth. The loss of GPR35 can attenuate pro-survival signaling, making cancer cells more susceptible to the effects of anticancer drugs, thereby potentially improving the efficacy of chemotherapy.

2. **NCOA7**: NCOA7 (Nuclear Receptor Coactivator 7) acts as a coactivator and has been associated with enhancing the sensitivity of cells to various pharmacological agents. Knockout of NCOA7 via CRISPR has been shown to affect cellular pathways linked to drug transport and metabolism, thus influencing drug activity. In pharmacogenomic studies, NCOA7 knockouts have been reported to modulate the response to drugs by altering the regulatory networks involved in drug detoxification pathways, potentially leading to enhanced drug efficacy in certain cellular contexts.

3. **LAG3**: Lymphocyte Activating 3 (LAG3) is an immune checkpoint receptor commonly found on activated T-cells. In cancer treatment, CRISPR-mediated knockout of LAG3 has been explored to enhance the activity of immunotherapy drugs such as checkpoint inhibitors. Knockout studies suggest that inhibiting LAG3 in the tumor microenvironment can boost the efficacy of these immunotherapeutics by allowing a more robust immune response against tumor cells. This has led to enhanced proliferation and cytotoxicity of T-cells, turning the immune system effectively against cancer cells and improving the overall therapeutic response.

4. **PTEN**: The PTEN gene is a well-known tumor suppressor. Its knockout has demonstrated variable effects on drug sensitivity depending on the cellular context. In some CRISPR knockout studies, loss of PTEN has led to enhanced sensitivity to specific targeted therapies, particularly in cancers where downstream signaling pathways like PI3K/Akt are activated upon PTEN deletion. However, due to PTEN’s role in maintaining cellular homeostasis, its knockout can have complex effects on drug responses, often necessitating combination therapies for effective treatment modulation.

These findings highlight the potential of using CRISPR technology to dissect gene-drug interaction networks, offering insights that could translate into more effective therapeutic strategies.